XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Jefferies Downgrades XOMA, Ltd. (XOMA) to Hold
July 23, 2015 7:23 AM EDTJefferies downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Hold with a price target of $1.00 (from $7.00).
Analyst Biren Amin commented, "XOMA announced that gevokizumab missed on the primary endpoint on time to first exacerbation in EYEGUARD-B for Behcets uveitis as a result of... More
Ladenburg Thalmann Downgrades XOMA, Ltd. (XOMA) to Neutral
July 22, 2015 2:32 PM EDTLadenburg Thalmann downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Neutral with a price target of $1.00 (from $6.00).
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $4.40 yesterday.
... MoreRBC Capital Downgrades XOMA, Ltd. (XOMA) to Sector Perform
July 22, 2015 1:38 PM EDTRBC Capital downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Sector Perform with a price target of $2.00 (from $8.00).
Analyst Adnan Butt said, "Phase III Behcets study was higher risk but going forward is likely to create uncertainty around Phase III... More
Cowen Downgrades XOMA, Ltd. (XOMA) to Market Perform
July 22, 2015 12:57 PM EDTCowen downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Market Perform after the company announced that gevo's EYEGUARD-B trial in Behçets uveitis did not meet its primary endpoint. The firm said the gevo's viability is now in question.
Analsyt Phil Nadeau... More
It's NOT 'Game Over' for XOMA (XOMA), Wedbush Says; PT to $13
July 22, 2015 12:55 PM EDTWedbush analyst Liana Moussatos cut here price target on XOMA, Ltd. (NASDAQ: XOMA) to $13.00 (from $17.00) after Gevokizumab failed to meet the primary endpoint in its Phase 3 EYEGUARDB trial in patients with Behçets disease uveitis (BDU). However, the firm maintained its Outperform rating saying it is... More
Piper Jaffray Downgrades XOMA, Ltd. (XOMA) to Neutral
July 22, 2015 11:11 AM EDTPiper Jaffray downgraded XOMA, Ltd. (NASDAQ: XOMA) from Overweight to Neutral.
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $4.40 yesterday.
... MoreXOMA (XOMA) Slammed 70% as Trading Resumes
July 22, 2015 8:33 AM EDTXOMA (NASDAQ: XOMA) has resumed trading and is down 67% after announcing the Phase 3 EYEGUARD-B study of gevokizumab in patients with Bechet's disease uveitis, run by its partner Servier, did not meet the primary endpoint of time to first acute ocular exacerbation.
... MoreXOMA (XOMA) to Resume Trading at 8:30 AM
July 22, 2015 8:03 AM EDTXOMA (NASDAQ: XOMA) to Resume Trading at 8:30 AM
... More